Trial Profile
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Metformin
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms AddHope2
- 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 19 Oct 2016 Results assessing the effect of liraglutide on heart rate and heart rate variability over 12 weeks published in the Diabetes Care.